California Prostate Cancer Coalition - CPCC

11/02/2024

National Alliance of State Prostate Cancer Coalitions is honoring CPCC Vice President Tom Kirk during the Board of Directors Meeting and their Annual Meeting where Tom served as Special Advisor.

02/29/2024

Please find the Livestream broadcast link to furnish to family members and guests who are unable to be physically present for the Funeral Service for Thomas N. Kirk.

https://hillsidememorial.livecontrol.tv/ca1bf176

The Service is scheduled for Friday March 1st at 2:00PM in the Small Chapel at Hillside Memorial Park.

02/27/2024

Services for my beloved husband Tom Kirk will take place this Friday, March 1, at Hillside Memorial Park (6001 W. Centinela Ave., Los Angeles 90045) at 2:00 pm in the small chapel. Please let me know if you have any questions. Merel mgrey@ucsd.edu

10/08/2023

California Prostate Cancer Coalition - CPCC President Merel Grey Nissenberg at last night's National Alliance of State Prostate Cancer Coalitions dinner.

10/07/2023

CPCC Board Member and Prostatepedia Editor Jessie Myers moderates a panel (Dr. Markowski, Dr. Morris, Dr. Armstrong, and Dr. Spratt) during the National Alliance of State Prostate Cancer Coalitions 18th Annual Meeting in DC.

10/15/2022

Tommorow us the day.Join us for our CPCC/UCSF 3rd Patient Conference on Prostate Cancer. Reegister here for event

CPCC and UCSF Present: The 2022 Patient Conference on Prostate Cancer (virtual)

07/14/2022

New Aetna Policy for PSMA Screening for PLUVICTO Radioligand Therapy

http://ow.ly/M6nY50JVtX0

Aetna Policy for PSMA Screening, Aetna Policy for PLUVICTO Radioligand Therapy, PLUVICTO Radioligand Therapy, PLUVICTO PSMA Screening for prostate cancer,

07/14/2022

Web-Based Peer Navigation for Men with Prostate Cancer and Their Family Caregivers: A Pilot Feasibility Study.

http://ow.ly/NIPT50JVtWk

07/14/2022

Patient-reported Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Harboring DNA Damage Response Alterations Treated with Talazoparib: Results from TALAPRO-1.

Talazoparib has shown antitumor activity with a manageable safety profile in men with metastatic castration-resistant prostate cancer (mCRPC) and DNA damage response (DDR)/homologous recombination repair (HRR) alterations.

07/14/2022

Neurotoxicities of Novel Non-Steroidal Anti-Androgens for Prostate Cancer: A Systematic Review and Meta-Analysis - Beyond the Abstract

http://ow.ly/HGST50JVtVm

07/14/2022

Variability in Testosterone Measurement Between Radioimmunoassay (RIA), Chemiluminescence Assay (CLIA) and Liquid Chromatography-Tandem Mass Spectrometry (MS) Among Prostate Cancer Patients on Androgen Deprivation Therapy (ADT) - Beyond the Abstract

testosterone levels for men on androgen deprivation therapy, castrate resistant prostate cancer (CRPC), androgen deprivation therapy (ADT), prostate cancer patients on androgen deprivation therapy (ADT), gold standard for testosterone measurement, Liquid chromatography-tandem mass spectrometry.

07/14/2022

Delta-like ligand 3-targeted radioimmunotherapy for neuroendocrine prostate cancer.

http://ow.ly/fpHf50JVtTB